These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 27779402)
1. Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay. Cannaert A; Storme J; Franz F; Auwärter V; Stove CP Anal Chem; 2016 Dec; 88(23):11476-11485. PubMed ID: 27779402 [TBL] [Abstract][Full Text] [Related]
2. Activity-Based Detection of Consumption of Synthetic Cannabinoids in Authentic Urine Samples Using a Stable Cannabinoid Reporter System. Cannaert A; Franz F; Auwärter V; Stove CP Anal Chem; 2017 Sep; 89(17):9527-9536. PubMed ID: 28771321 [TBL] [Abstract][Full Text] [Related]
3. Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors. Noble C; Cannaert A; Linnet K; Stove CP Drug Test Anal; 2019 Mar; 11(3):501-511. PubMed ID: 30280499 [TBL] [Abstract][Full Text] [Related]
4. Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. Banister SD; Stuart J; Kevin RC; Edington A; Longworth M; Wilkinson SM; Beinat C; Buchanan AS; Hibbs DE; Glass M; Connor M; McGregor IS; Kassiou M ACS Chem Neurosci; 2015 Aug; 6(8):1445-58. PubMed ID: 25921407 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive investigation on synthetic cannabinoids: Metabolic behavior and potency testing, using 5F-APP-PICA and AMB-FUBINACA as model compounds. Fabregat-Safont D; Mardal M; Noble C; Cannaert A; Stove CP; Sancho JV; Linnet K; Hernández F; Ibáñez M Drug Test Anal; 2019 Sep; 11(9):1358-1368. PubMed ID: 31192526 [TBL] [Abstract][Full Text] [Related]
7. Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ Hutchison RD; Ford BM; Franks LN; Wilson CD; Yarbrough AL; Fujiwara R; Su MK; Fernandez D; James LP; Moran JH; Patton AL; Fantegrossi WE; Radominska-Pandya A; Prather PL Front Pharmacol; 2018; 9():1084. PubMed ID: 30319418 [TBL] [Abstract][Full Text] [Related]
8. Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice. Vigolo A; Ossato A; Trapella C; Vincenzi F; Rimondo C; Seri C; Varani K; Serpelloni G; Marti M Neuropharmacology; 2015 Aug; 95():68-82. PubMed ID: 25769232 [TBL] [Abstract][Full Text] [Related]
9. [Evaluation of an on-site drug-testing device for the detection of synthetic cannabinoids in illegal herbal products]. Uchiyama N; Kikura-Hanajiri R; Hakamatsuka T Yakugaku Zasshi; 2015; 135(3):535-41. PubMed ID: 25759062 [TBL] [Abstract][Full Text] [Related]
10. Molecular Pharmacology of Synthetic Cannabinoids: Delineating CB1 Receptor-Mediated Cell Signaling. Walsh KB; Andersen HK Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854313 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACA. Longworth M; Connor M; Banister SD; Kassiou M ACS Chem Neurosci; 2017 Aug; 8(8):1673-1680. PubMed ID: 28574245 [TBL] [Abstract][Full Text] [Related]
12. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice. Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953 [TBL] [Abstract][Full Text] [Related]
13. Concentrations of APINACA, 5F-APINACA, UR-144 and its degradant product in blood samples from six impaired drivers compared to previous reported concentrations of other synthetic cannabinoids. Karinen R; Tuv SS; Øiestad EL; Vindenes V Forensic Sci Int; 2015 Jan; 246():98-103. PubMed ID: 25485949 [TBL] [Abstract][Full Text] [Related]
14. Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens. Wohlfarth A; Scheidweiler KB; Castaneto M; Gandhi AS; Desrosiers NA; Klette KL; Martin TM; Huestis MA Clin Chem Lab Med; 2015 Feb; 53(3):423-34. PubMed ID: 25263309 [TBL] [Abstract][Full Text] [Related]
15. Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. Pinson A; Yarbrough AL; Bush JM; Cabanlong CV; Shoeib A; Jackson BK; Fukuda S; Gogoi J; Fantegrossi WE; McCain K; Prather PL; Fujiwara R; Radominska-Pandya A Pharmacol Biochem Behav; 2020 Aug; 195():172949. PubMed ID: 32413436 [TBL] [Abstract][Full Text] [Related]
17. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Möller I; Wintermeyer A; Bender K; Jübner M; Thomas A; Krug O; Schänzer W; Thevis M Drug Test Anal; 2011 Sep; 3(9):609-20. PubMed ID: 20872894 [TBL] [Abstract][Full Text] [Related]
18. Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated using LC-HR-MS/MS: Do they reflect patterns in humans? Schaefer N; Helfer AG; Kettner M; Laschke MW; Schlote J; Ewald AH; Meyer MR; Menger MD; Maurer HH; Schmidt PH Drug Test Anal; 2017 Apr; 9(4):613-625. PubMed ID: 27328899 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of emerging synthetic cannabinoids in HEK293T cells and hippocampal neurons. Costain WJ; Tauskela JS; Rasquinha I; Comas T; Hewitt M; Marleau V; Soo EC Eur J Pharmacol; 2016 Sep; 786():234-245. PubMed ID: 27260125 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the Neurotoxic and Seizure-Inducing Effects of Synthetic and Endogenous Cannabinoids with Δ Breivogel CS; Wells JR; Jonas A; Mistry AH; Gravley ML; Patel RM; Whithorn BE; Brenseke BM Cannabis Cannabinoid Res; 2020 Mar; 5(1):32-41. PubMed ID: 32322674 [No Abstract] [Full Text] [Related] [Next] [New Search]